References
- Jurcevic S, Klinga-Levan K, Olsson B, Ejeskär K. Verification of microRNA expression in human endometrial adenocarcinoma. BMC Cancer 2016; 16: 261. doi: 10.1186/s12885-016-2296-z
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-86. doi: 10.1002/ijc.29210
- Zhang H, Yan L, Bai Y, Li C, Guo Q, Wang C, et al. Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia. Gynecol Oncol 2015; 136: 549-53. doi: 10.1016/j. ygyno.2014.11.008
- Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W, et al. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000; 7: 227-42.
- Cavanagh D, Fiorica JV, Hoffman MS, Durfee J, Nicosia SV. Adenocarcinoma of the endometrium: an Institutional review. Cancer Control 1999; 6: 354-60. doi: 10.1177/107327489900600405
- Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005; 366: 491-505. doi: 10.1016/S0140-6736(05)67063-8
- Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1995; 154: 8-20.
- Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-90. doi: 10.1016/j. cell.2009.11.007
- Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 2004; 10: 4125-33. doi: 10.1158/1078-0432.CCR-0578-03
- Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 813-22. doi: 10.1038/ sj.onc.1202367
- Zhang Z, Kobayashi S, Borczuk AC, Leidner RS, Laframboise T, Levine AD, et al., Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 2010; 31: 577-86. doi: 10.1093/carcin/bgq020
- Chan DW, Liu VW, Tsao GS, Yao KM, Furukawa T, Chan KK, et al. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 2008; 29: 1742-50. doi: 10.1093/carcin/bgn167
- Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 2003; 162: 1807-15. doi: 10.1016/S0002-9440(10)64315-5
- Patterson KI, Brummer T, O’Brien PM, Daly RJ. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 2009; 418: 475-89. doi: 10.1042/bj20082234
- Arkell RS, Dickinson RJ, Squires M, Hayat S, Keyse SM, Cook SJ. DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5. Cell Signal 2008; 20: 836-43. doi: 10.1016/j.cellsig.2007.12.014
- Jurek A, Amagasaki K, Gembarska A, Heldin CH, Lennartsson J. Negative and positive regulation of MAPK phosphatase 3 controls platelet-derived growth factor-induced Erk activation. J Biol Chem 2009; 284: 4626-34. doi: 10.1074/ jbc.M808490200
- Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell 2010; 38: 114-27. doi: 10.1016/j.molcel.2010.02.020
- Chen HX, Xu XX, Tan BZ, Zhang Z, Zhou XD. MicroRNA-29b Inhibits angiogenesis by targeting VEGFA through the MAPK/ERK and PI3K/Akt signaling pathways in endometrial carcinoma. Cell Physiol Biochem 2017; 41: 933-46. doi: 10.1159/000460510
- Wang D, Wang D, Wang N, Long Z, Ren X. Long non-coding RNA BANCR promotes endometrial cancer cell proliferation and invasion by regulating MMP2 and MMP1 via ERK/MAPK signaling pathway. Cell Physiol Biochem 2016; 40: 644-56. doi: 10.1159/000452577
- Ma Z, Liu X, Li F, Wang Y, Xu Y, Zhang M, et al. Perfluorooctanoic acid induces human Ishikawa endometrial cancer cell migration and invasion through activation of ERK/mTOR signaling. Oncotarget 2016; 7: 66558-68. doi: 10.18632/oncotarget.11684
- Wong VC, Chen H, Ko JM, Chan KW, Chan YP, Law S, et al. Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. Int J Cancer 2012; 130: 83-95. doi: 10.1002/ijc.25970
- Wu QN, Liao YF, Lu YX, Wang Y, Lu JH, Zeng ZL, et al. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. Cancer Lett 2018; 412: 243-55. doi: 10.1016/j. canlet.2017.10.007
- Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17: 548-58. doi: 10.1016/j.ceb.2005.08.001
- McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 2016; 7: 418-9. doi: 10.3945/an.116.012211.
- Zhang H, Guo Q, Wang C, Yan L, Fu Y, Fan M, et al. Dual-specificity phosphatase 6 (Dusp6), a negative regulator of FGF2/ERK1/2 signaling, enhances 17β-estrodial-induced cell growth in endometrial adenocarcinoma cell. Mol Cell Endocrinol 2013; 376: 60-9. doi: 10.1016/j.mce.2013.02.007
- Mayama T, Fukushige S, Shineha R, Nishihira T, Satomi S, Horii A, et al. Frequent loss of copy number on the long arm of chromosome 21 in human esophageal squamous cell carcinoma. Int J Oncol 2000; 17: 245-52.
- Lo KW, Teo PM, Hui AB, To KF, Tsang YS, Chan SY, et al. High resolution allelotype of microdissected primary nasopharyngeal carcinoma. Cancer Res 2000; 60: 3348-53. doi: 10.3892/ijo.17.2.245
- Shaw KR, Wrobel CN, Brugge JS. Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J Mammary Gland Biol Neoplasia 2004; 9: 297-310. doi: 10.1007/s10911-004-1402-z
- Liu LK, Jiang XY, Zhou XX, Wang DM, Song XL, Jiang HB, et al. Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol 2010; 23: 213-24. doi: 10.1038/ modpathol.2009
- Camps M, Nichols A, Gillieron C, Antonsson B, Muda M, Chabert C, et al. Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. Science 1998; 280: 1262-5. doi: 10.1126/sci-ence.280.5367.1262